Mineralys: Jon Congleton proposes $1.91M share sale

The notice also reports two earlier common-stock sales by Jon Congleton, dated June 30 and July 13, 2026.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) is the issuer named in Jon Congleton’s notice of a proposed sale of 75,000 common shares, with an aggregate market value of $1,909,661.61. Congleton is identified as an officer and director; the securities information lists 88,406,885 shares outstanding as of September 30, 2026. The notice also lists prior sales by Congleton: 75,000 shares for $1,960,601.58 on June 30, 2026, and 10,700 shares for $291,441.17 on July 13, 2026.

Key Figures

Proposed sale: 75,000 common shares Aggregate market value of proposed sale: $1,909,661.61 Shares outstanding: 88,406,885 shares +2 more

5 metrics

Proposed sale 75,000 common shares Jon Congleton’s notice

Aggregate market value of proposed sale $1,909,661.61 Jon Congleton’s notice

Shares outstanding 88,406,885 shares As of September 30, 2026

Prior sale 75,000 common shares June 30, 2026; aggregate market value $1,960,601.58

Prior sale 10,700 common shares July 13, 2026; aggregate market value $291,441.17

Key Terms

Rule 144, restricted stock unit awards, issuer equity compensation plan

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock unit awards financial

"Vesting of Restricted Stock Unit Awards"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

issuer equity compensation plan financial

"Granted as part of issuer equity compensation plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MLYS shares did Jon Congleton propose to sell?

Jon Congleton gave notice of a proposed sale of 75,000 Mineralys common shares, with an aggregate market value of $1,909,661.61. The securities information lists 88,406,885 shares outstanding as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 04:08 PM Accepted by SEC EDGAR 09/30/2026 - 04:07 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001644975
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Congleton Jon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St 37th Floor New York NY 10281	75000	1909661.61	88406885	09/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/10/2025	Vesting of Restricted Stock Unit Awards	Mineralys Therapeutics, Inc.			3194	01/10/2025	Granted as part of issuer equity compensation plan
Common Stock	04/10/2025	Vesting of Restricted Stock Unit Awards	Mineralys Therapeutics, Inc.			20635	04/10/2025	Granted as part of issuer equity compensation plan
Common Stock	07/10/2025	Vesting of Restricted Stock Unit Awards	Mineralys Therapeutics, Inc.			20070	07/10/2025	Granted as part of issuer equity compensation plan
Common Stock	10/10/2025	Vesting of Restricted Stock Unit Awards	Mineralys Therapeutics, Inc.			20854	10/10/2025	Granted as part of issuer equity compensation plan
Common Stock	01/10/2026	Vesting of Restricted Stock Unit Awards	Mineralys Therapeutics, Inc.			10247	01/10/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/30/2026	75000	1960601.58
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/13/2026	10700	291441.17

144: Remarks and Signature

Remarks
Date of Notice	09/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/23/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jon Congleton
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)